TdT activity in acute myeloid leukemias defined by monoclonal antibodies

Abstract

Blast cells from eight out of 71 patients diagnosed with acute myeloid leukemia (AML) by morphological, cytochemical, and immunological criteria showed TdT activity. Their distribution according to the FAB classification was one M1, one M2, one M4, two M5a, one M5b, one M6, and one undifferentiated case. The TdT⁺ AML cases did not show major clinical and hematological differences when compared with the classical TdT⁻ AML patients. Other phenotypical aberrations in the expression of membrane antigens, apart from the presence of nuclear TdT, were not observed in these TdT⁺ cases after study with a large panel of monoclonal antibodies. A higher incidence of TdT⁺ cases was found among the monocytic variants of AML (M4 and M5)‐four cases‐than in the granulocytic variants (M1, M2, and M3)‐2 cases. These TdT⁺ cases should be distinguished from mixed leukemias by double labeling techniques, assessing in the TdT⁺ AML the coexpression of TdT and myeloid markers in individual cells as shown in four of our cases.